Protocol Design Featured Articles

  1. What Ecological Momentary Assessment Taught Us About Real-World Hearing Outcomes 10/5/2026

    Ecological momentary assessment (EMA) reveals how people experience hearing challenges beyond the clinic. Here, researchers highlight its relevance in designing real-world hearing studies.

  2. Calidi's Study Aims To Have An Oncolytic Virus Outsmart The Immune System 10/2/2026

    Calidi’s Eric Poma, Ph.D., explains how CLD-401 could evade immune clearance — and how the biotech is designing Phase 1 to prove safety and efficacy fast.

  3. New Imaging Approach Could Improve IPF Trial Design 10/1/2026

    AI-powered quantitative CT could help sponsors detect treatment effects earlier, strengthen IPF trial endpoints, and make better go/no-go decisions.

  4. How Digital Twins Are Reshaping Clinical R&D 9/28/2026

    Discover how digital twins are helping predict outcomes, streamline recruitment, reduce patient burden, and accelerate clinical development.

  5. Examining The Potential Of P-tau217 To Provide Earlier Diagnosis Of Alzheimer's 9/25/2026

    P-tau217 blood tests could accelerate Alzheimer’s diagnosis. Lilly’s Nino Sireci, MD, MSc, explains the research, evidence thus far, potential clinical use, and next steps.

  6. How VNS-REHAB Aims To Improve Stroke Recovery After Patients Have Plateaued 9/22/2026

    Learn how a stroke trial standardized intensive therapy, sustained patient adherence, and exposed access barriers after FDA approval.

  7. Why Oncology Programs Can't Rely On An Inside View Alone 9/18/2026

    Discover how looking outside a program can help oncology teams test assumptions, improve feasibility, and make stronger development decisions.

  8. Before Adding AI, Fix The Process 9/17/2026

    Regeneron’s Kaniel Cassady argues that “doing more with less” in clinical development should start with questioning existing processes, unnecessary data collection, and outdated workflows before turning to AI and other new technologies.

  9. Repurposing Three FDA-Approved Drugs For A New Stroke Recovery Strategy 9/17/2026

    When three drugs become one — the polypharmacology strategy, 505(b)(2) pathway, and objective endpoints Nuero-Innovators is relying on to bring new hope to stroke patients.

  10. Medical Affairs: The Missing Link To Oncology Drug Adoption 9/11/2026

    Learn how medical affairs can help oncology teams turn strong clinical evidence into real-world adoption by connecting development strategy with clinical practice.